In this video, Dr. Michael Sherman, Senior Vice President and Chief Medical Officer at Harvard Pilgrim Heath Care, discusses the evolution of companion diagnostic testing, and some of the concerns with cost and coding.
In this video, Dr. Michael Sherman, Senior Vice President and Chief Medical Officer at Harvard Pilgrim Heath Care, discusses the evolution of companion diagnostic testing, and some of the concerns with cost and coding.
This video was taken at the 4th Annual Forum for Payers on Personalized Medicine conference in Washington, DC, on March 12, 2012.
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More